• Study plan of AlzeCure’s Phase II clinical study in neuropathic pain with non-opioid ACD440 now available

  • First patient included in AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440

  • Positive data from the clinical phase I MAD study with AlzeCure's Alzheimer's project NeuroRestore ACD856

AlzeCure Pharma

AlzeCure Pharma is a Swedish pharmaceutical company focusing on the research and development of innovative and efficacious treatments for Alzheimer’s disease and related disorders

Research

AlzeCure is developing disease modifying and symptomatic first in class treatments for Alzheimer’s disease and other conditions characterized by cognitive dysfunction

Alzheimer’s Disease

Alzheimer’s disease is a deadly disorder which lacks effective treatments. The need for novel treatments is therefore urgent.